Dennis Moledina, MD PhD

Nephrologist and physician-scientist @YaleMed @YaleIMed Assistant Professor

[Dennis Moledina, MD PhD @dmoledina]

A brief thread on our recently published work on CXCL9 as a diagnostic biomarker for acute tubulointerstitial nephritis (AIN) https://t.co/CMFcuvCgVI @jclinicalinvest @YaleMed @YaleIMed @YaleNephrology @KidneydrChirag @fperrywilson

[Yale Internal Medicine @YaleIMed]

1 in 5 patients develops acute kidney injury (AKI) within the first year of starting cancer immunotherapy.

Researchers are investigating whether checkpoint inhibitors are causing acute interstitial nephritis.

Read more in the Q&A with @dmoledina.

https://t.co/GZPaG8t1Ir

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@PAWellingMD @KidneydrChirag The value of KPMP is starting…congrats…great work.

https://t.co/OehlHsC8Iv

[Hopkins Med News @HopkinsMedNews]

New @hopkinsneph study uses new electronic diagnostic model as an alternative to kidney biopsies to predict AIN. @KidneydrChirag
https://t.co/dDLDboUpUg

[Chirag Parikh @KidneydrChirag]

This important advance was greatly enabled by superstars who are developing kidney biopsy registries at their institutions @dmoledina @StevenMenez

[Chirag Parikh @KidneydrChirag]

I hope people will use the AIN calculator to differentiate AIN from ATN on AKI consults. Let us know if you have questions or additional suggestions. @dmoledina

[Yale Nephrology @YaleNephrology]

📸 Tiffany B from @lloydcantley1 presenting her IMC work @KPMProject
📸 Sagar S and @KidneydrChirag presenting a poster together @dmoledina @fperrywilson
📸 Bhavya B focused on her work in @lloydcantley1 lab
📸 More HRS data from @jmbnephdoc
So much to see! #KidneyWk

[Yale Nephrology @YaleNephrology]

Dr. Leyuan Xu presenting the Immune Landscape of AKI in 6B at @ASNKidney #KidneyWk now! Excellent talk and excellent summary slide! @lloydcantley1 @dmoledina @PKDSteve @KidneydrChirag

[Yale Nephrology @YaleNephrology]

📸 @meganlebaker giving her first oral presentation at @ASNKidney #KidneyWk this afternoon, on her work characterizing immune-tubulointerstitial interactions in AIN and ATI! @lloydcantley1 @dmoledina

[Yale Nephrology @YaleNephrology]

New in @JASN_News : external validation of a diagnostic model for predicting biopsy-proven AIN increased AUC of clinicians' prebiopsy suspicion for AIN by 0.10 to 0.77! Awesome tool!

@dmoledina @Nephronette @fperrywilson @KidneydrChirag @YaleIMed

https://t.co/Rj8i2cthue

[JASN_News @JASN_News]

Accurate diagnosis of acute tubulointerstitial nephritis (AIN) often requires a kidney biopsy. This study found that an AIN diagnostic model retained discrimination in two validation cohorts but needed recalibration to account for local AIN prevalence. https://t.co/GyqeGwIf62
@dmoledina @fperrywilson @kidneydrchirag @Nephronette @oconnkyle @StevenMenez

[Yale School of Medicine @YaleMed]

A new #clinicaltrial led by @YaleIMed's @dmoledina seeks to use biomarkers to detect when kidney injury results from #immunotherapy complications, reducing treatment interruptions for patients with #cancer. Learn more in a YSM Q&A: https://t.co/yGKezi6RWj

[Dennis Moledina, MD PhD @dmoledina]

@hswapnil @NephroGuy @rmohty @onconephsociety We had urine PDL1 (not PD1) in our olink proteomics data. 1.7 fold higher in AIN (pval=0.007, qval=0.03). CXCL9 was 7.6-fold higher in AIN.

[Dennis Moledina, MD PhD @dmoledina]

@hswapnil @NephroGuy @rmohty @onconephsociety very cool study - urine sPD1 could be a biomarker of ICI-AIN vs. other AIN (2.7 fold higher). i can't figure out if there is any difference in non-ICI-AIN vs. ATN. We didn't measure this so can't really tell which one performs better (CXCL9 vs. PD1).

[Dennis Moledina, MD PhD @dmoledina]

@SWadhwaniMD @NU_Nephrology @OhioStateNeph @Rush_Nephrology Congratulations!!

[Dennis Moledina, MD PhD @dmoledina]

@hswapnil @NephroSeeker @NephJC This is the really good study looking at PPI-AIN /PPI-AKI. 2-3 fold higher hazard of both but low incidence of bx-proven AIN (though certainly some could’ve been missed). https://t.co/QeS47Pdft7

[Yale Cancer Center @YaleCancer]

Dr. Dennis Moledina @dmoledina discusses his research into identifying and validating #biomarkers for the diagnosis of acute interstitial #nephritis. Watch his #GrandRounds talk now https://t.co/ysZOCkQSS6. #kidneycancer @SmilowCancer @YaleMed @YNHH

[Dennis Moledina, MD PhD @dmoledina]

Dr Erin Barreto @erin_barreto - medication management in AKI: moving beyond “medications reviewed” #NKFClinicals

[Dennis Moledina, MD PhD @dmoledina]

#NKFClinicals interprofessional care of patients with AKI: it takes a village @JeffNeph @javo_neyra @erin_barreto

[Dennis Moledina, MD PhD @dmoledina]

Multidisciplinary Care of Patients Hospitalized with AKI - @javo_neyra kicking off the session #NKFClinicals

[Dennis Moledina, MD PhD @dmoledina]

Dr Turner @JeffNeph talking about updates in cardiorenal syndrome #NKFClinicals

[Dennis Moledina, MD PhD @dmoledina]

Happening now at #NKFClinicals AKI syndromes: special considerations with @VelezNephHepato @JeffNeph Dr Nelson Leung. Room 104b

[Dennis Moledina, MD PhD @dmoledina]

@VelezNephHepato Next from the Mayo Clinic - Dr. Nelson Leung. #NKFClinicals cancer and chemotherapy associated kidney injury